Sudden cardiac death, usually due to a ventricular tachyarrhythmia, accounts for 350 000 to 400 000 deaths annually in the United States and continues to be a major public health problem. Although there is a tendency to focus on sudden cardiac death as a distinct clinical entity, sudden death is more correctly viewed as a ubiquitous final common pathway for a spectrum of cardiac pathologies. Sudden cardiac death has been implicated as a major cause of mortality in every form of heart disease associated with significant regional or global abnormalities of function. In the adult population, coronary artery disease represents the most common cardiac substrate.
Cohort studies of patients who have survived an episode of sudden death have been crucial to understanding this problem. These studies have resulted in the development of a series of strategies that use serial electropharmacological testing, map-guided surgery, and antiarrhythmic devices for treatment of these patients. However, only 1% to 20% of patients experiencing out-of-hospital sudden death survive to hospital discharge.1-3 Thus, aggressive treatment of sudden death survivors cannot significantly affect sudden death mortality. 4 The public health aspects of sudden cardiac death can only be addressed by a multifaceted approach that includes prevention of heart disease, widespread cardiopulmonary resuscitation training, identification of the patient at increased risk for sudden death, and intervention to prevent sudden death focused on these high-risk individuals. The primary purpose of this article is to review the major efforts to identify the patient at high risk for sudden arrhythmic death and to highlight both completed and ongoing efforts to prevent manifestation of this clinical entity. The implications of recently completed and ongoing studies concerning patients with clinically manifest sustained arrhythmias are also briefly discussed.
Sudden Death Prediction
Since the risk of sudden cardiac death in the unselected adult population is only 2 per 1000 persons per year, screening of unselected patients is impractical.5 As a result, risk stratification efforts have focused on groups with known heart disease. The most convenient group for risk stratification studies is the post-myocardial infarction (MI) patient population. Techniques reported to be of value in identifying high-risk patients include (1) ambulatory electrocardiographic recordings, (2) measurement of left ventricular function, (3) signalaveraged electrocardiography, (4) assessment of heart rate variability, (5) determination of reflex baroreceptor sensitivity, (6) identification of repolarization alternans, and (7) invasive electrophysiological testing. Ambulatory Electrocardiography Observations in coronary care units indicate that sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) are often preceded by frequent or complex ventricular ectopy.6,7 Epidemiological observations also indicate that ventricular premature complexes (VPCs) in ambulatory patients are associated with an increased incidence of sudden death.8 Long-term ambulatory recordings increase the sensitivity for detection of asymptomatic arrhythmias and reduce errors due to variability in the occurrence of VPCs and complex ventricular arrhythmias.9,0 However, day-to-day variability as well as long-term variability due to a changing cardiac substrate still must be taken into account when using Holter monitoring techniques.11' 2 Kotler et al13 reported the prognostic importance of ambulatory electrocardiographic findings in 160 post-MI patients. America67 are concordant and provide compelling evidence that vasodilators reduce overall mortality as well as mortality due to progressive heart failure. However, the studies that examined cause-specific mortality, ie, sudden versus nonsudden death, have seemingly disparate results. The SOLVD investigators65 found no effect of enalapril on sudden cardiac death in patients with reduced (less than 35%) ejection fractions and no prior treatment for congestive heart failure. The CONSEN-SUS I trial reported66 a similar finding in severely symptomatic patients (New York Heart Association Class IV congestive failure). In contrast, the V-HEFT II study reported64 a significant reduction in sudden death when enalapril was used rather than hydralazine and nitrates in symptomatic patients with noninvasive evidence of cardiac dysfunction.
The discrepancies among the vasodilator trials in reported effects on sudden death warrant consideration. The different patient populations studied presumably account for some of the differences. Relatively asymptomatic patients (SOLVD study) appear to have a better prognosis from the standpoint of sudden death than patients with more symptoms and the same degree of ventricular dysfunction.68 On the other extreme, prognosis in severely ill patients (CONSENSUS I) may be so dependent on the degree of heart failure that sudden death intervention has minimal effect. Only 26% of the deaths in the CONSENSUS I trial were sudden deaths, less than in the other trials. 66 Patients with intermediate symptoms, such as the V-HEFT patients, may be the most likely to benefit from therapy. Apparent differences may also be due to the different definitions of sudden cardiac death used in the various studies.
The mechanism by which angiotensin-converting enzyme inhibitors reduce sudden death remains to be elucidated. The Amiodarone was excluded from the CAST investigations as well as many earlier controlled trials because of its complicated pharmacokinetics and concern for the incidence of end-organ toxicity. However, the low incidence of significant proarrhythmia and the demonstration that most pulmonary toxicity is avoidable at lowdose ranges have resulted in considerable interest in the use of this agent for sudden death prophylaxis.77 In the Basel Antiarrhythmic Study (BASIS),78 post-MI patients with complex ventricular ectopy were randomized to empiric low-dose amiodarone (200 mg/d), individualized therapy guided by Holter, or no treatment. Total mortality was less at 1 year of follow-up in the amiodarone group than in the control group. Total mortality differences between the amiodarone group and the Holterguided therapy group were not significantly different. Due to the relatively small number of patients studied, differences in sudden death mortality were not significantly different between any two of the three groups. In comparison with control subjects, the improved survival of the amiodarone-treated patients has persisted throughout an average follow-up of 6 years. 79 Surprisingly, post hoc subgroup analysis indicates that the beneficial effects of amiodarone were limited to those patients with ejection fractions greater than 40%. 80 Ceremuzynski et a181 have recently reported a randomized, double-blind, placebo-controlled trial of amiodarone in maintenance doses of 100 to 400 mg/d in post-MI patients. Patients were selected for the study specifically because they had clinical contraindications to 1-blockade such as heart failure, asthma, diabetes, or symptomatic peripheral arteriosclerosis. Lack of ventricular function, Holter assessment, or signal-averaged electrocardiographic criteria were used to screen patients for the study. Total mortality as well as cardiac mortality were both significantly reduced in the amiodarone treatment group. There was a 30% occurrence of some adverse reaction to amiodarone therapy. However, most reactions were fairly minor and pulmonary toxicity occurred in only one patient. 81 The results of this study suggest that amiodarone may be useful in the post-MI patient who has a contraindication to (-blockade.
A larger role for amiodarone in the management of patients after MI is under investigation in complementary multicenter trials in Europe and Canada. Patients in the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) are selected on the basis of ventricular arrhythmias on Holter recorded soon after infarction. In the European Myocardial Infarction Arrhythmia Trial (EMIAT), patients are selected on the basis of a reduced ejection fraction without regard to arrhythmia status. Both studies use low dose-amiodarone (less than 400 mg/d) and have similar end points, ie, total and cardiovascular mortality. In a small CAM-IAT pilot study82 a trend toward a reduction in the incidence of arrhythmic death or resuscitated ventricular fibrillation was observed with amiodarone treatment. More importantly, the incidence of amiodarone toxicity was sufficiently low to sanction the larger CAM-IAT study. The results of CAMIAT and EMIAT are much anticipated: these two studies should clarify the role of amiodarone in the post-MI patient.
The favorable hemodynamic profile of amiodarone has resulted in interest in its use to prevent sudden death in patients with dilated cardiomyopathy. In uncontrolled series, Cleland et al83'84 report favorable effects of amiodarone in patients with heart failure. A randomized, controlled trial of amiodarone is being conducted by the Veterans Administration in patients with congestive heart failure who are being treated concomitantly with angiotensin-converting enzyme inhibitors or other vasodilators. 85 Finally, McKenna et a186 report that amiodarone therapy reduced the incidence of sudden death in a high-risk group of 53 hypertrophic cardiomyopathy patients. No Empiric amiodarone has been used for years with anecdotal reports of a high efficacy rate. In large reported series, amiodarone efficacy correlates poorly with sustained arrhythmia induction at baseline electrophysiological study or demonstration of arrhythmia suppression on repeat study.'05 106Thus, prospective controlled trials of empiric amiodarone use in patients with malignant arrhythmias are warranted. In the Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) trial,'07 amiodarone reduced the incidence of sudden cardiac death compared with other antiarrhythmics guided by serial electrophysiological testing. However, sudden death rates were quite high in both groups, causing the investigators to implant cardioverter-defibrillators in over 40% of the study population.
The role of empiric amiodarone will be better defined when the results of two ongoing trials, the Canadian Implantable Defibrillator Study (CIDS) 108 First, the prophylactic therapies best substantiated by scientific data are substrate-oriented therapies rather than antiarrhythmic therapies per se. We would include in this group of well-substantiated therapies the use of }3-blockers in the post-MI patient population as well as the use of angiotensin-converting enzyme inhibitors in some subsets of patients with congestive heart failure. We would also include the use of revascularization in patients with diffuse coronary disease and left ventricular dysfunction in the group of effective therapies, although this treatment measure has not been tested as rigorously as the use of }3-blockers post-MI or angiotensin-converting enzyme inhibitors in congestive heart failure. Each of these therapies ameliorates the underlying cardiac pathology. Arrhythmia-focused therapy has failed when employed prophylactically. Whether the morbidity, mortality, and expense of device-based therapy will fare better than treatment with antiarrhythmic drugs remains to be seen.
Second, the mechanisms of action of the effective therapies are poorly understood. It is not known whether the benefits of p-blocking agents are due to their anti-ischemic or antiarrhythmic properties. Nor is the precise mechanism known by which angiotensinconverting enzyme inhibition prevents sudden death. These agents are primarily known for their hemodynamic effects but also have anti-ischemic properties. Treatment of congestive heart failure with angiotensinconverting enzyme inhibitors also influences the autonomic nervous system, which may be important in arrhythmia prevention. The antiarrhythmic agent that currently holds the most promise for sudden death prophylaxis, amiodarone, has very complex cardiac effects. It has a favorable hemodynamic profile in heart failure and was first developed as an antianginal drug. If this drug is proven to be effective for sudden death prevention, it will be difficult to determine which of these effects is more responsible for the benefit.
Third, risk stratification remains inadequate. In 1994, an outpatient angiogram can confirm the diagnosis of coronary disease in minutes. An echocardiogram can indicate the need for therapy for ventricular dysfunction in even less time. By comparison, selection of patients for sudden death prophylaxis remains inexact; many patients must be subjected to prophylactic medication or device implantation who would not experience sudden death if left untreated. We do not wish to appear overly critical of efforts designed to refine risk-stratification processes. We do wish to highlight the relative lack of understanding of the basic pathophysiology of sudden cardiac death compared with our understanding in other areas of cardiac disease expression. A better basic understanding is crucial if significant breakthroughs are to occur in risk stratification and prophylactic therapy reserved for those patients at greatest risk.
Review of past experience of efforts to prevent sudden death indicates that skepticism regarding new therapies is healthy. This applies to the two treatment modalities currently receiving the most attention, amiodarone and the prophylactic use of implantable devices. Amiodarone has yet to be conclusively shown to be beneficial to patients able to take p-blockers. Furthermore, patients in the large prospective trials will require several years of follow-up before it can be determined whether any treatment benefit outweighs long-term toxicity. While there is little debate that implantable cardioverter-defibrillators prevent sudden death, uncontrolled series have overemphasized the benefits of device therapy. Carefully analyzed controlled trials using total mortality as the primary end point must be completed before the practice of prophylactic device implantation becomes widespread.
Finally, we wish to point out that any small amount of progress toward a clinical solution to the problem of sudden cardiac death has been the product of prospective trials adhering to established scientific principles that have been organized and supported by large numbers of clinicians. This support must continue. The financial burden for this approach is often borne jointly by governmental agencies, the health care industry, and private philanthropy. Progress with this approach has been slow with advances occurring piecemeal. This approach requires patience on the part of health care consumers and their physicians. Nevertheless, until such time that a quantum breakthrough occurs in our understanding of the pathophysiology of sudden death, this is the only approach that has a reasonable chance of success. While progress is expensive, the cost is much less than that of supporting a number of potential therapies that are ineffective or even harmful. 
